MENU

Development, assessment and commercialization of serological SARS CoV-2 tests - an interdisciplinary success story

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • CEO Novasign GmbH, Project Lead BOKU - Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna
    BIOGRAPHY

Abstract

Antibody tests are important tools to assess the efficacy of vaccine candidates and to derive suitable vaccination modalities. High specificity and sensitivity are of great importance for the quality of an antibody test. Over the past five months, BOKU has been working intensively on the production of various SARS CoV-2 antigens in different biotechnological production systems. The aim was to identify antigen variants for the improved detection of SARS CoV-2 antibodies and to develop sustainable production processes for their high-quality supply. In order to rapidly screen a wide range of antigen candidates generated in different expression platforms, BOKU closely collaborated with the University of Veterinary Medicine Vienna. There, all BOKU antigens were pre-assessed in ELISA assays with a panel of pre-COVID control sera and selected sera of COVID19 patients. In addition, all proteins were also tested for SARS CoV-2 antibodies with the Luminex platform at the Austrian Institute of Technology and the Medical University Vienna. Based on the immunoassay results as well as antigen production yield and suitability for process scale-up, a truncated variant of the SARS CoV-2 spike receptor-binding domain (RBD) produced in a human cell line and the viral nucleocapsid protein (NP), produced in bacteria, were selected for further assay development. BOKU established complex multi-step purification processes and analytics with multiple antigen batches to ensure that the high-quality standards required for diagnostic protein reagents are always met. For prolonged antigen and test supply, two Viennese companies, that already provided knowledge and technology in the development phase, are now commercializing the diagnostic antigens and serological tests. Technoclone GmbH optimized the ELISA protocol and now offers both the RBD and NP ELISA Test “made in Austria”. EnGenes Biotech GmbH now commercially produces and distributes SARS CoV-2 antigens. The excellent interaction between the cooperating universities, research institutions and companies in this unique cross competence approach has paid off, as the tests achieved excellent scores in clinical validations performed at the Department of Laboratory Medicine at MedUni Vienna. The tests not only allow for highly specific and sensitive detection of SARS CoV-2 antibodies, the RBD test results also correlate well with the titers of neutralizing antibodies present in sera of COVID19 patients.

Learning Objectives:

1. Quantitative SARS-CoV2 Antibody tests, basted on SARS-CoV2 receptor binding domain and highly pure nucleocapsid protein for vaccination monitoring

2. Antigen quality assessment compared with both ELISA and LUMINEX in over 2000 sampels

3. Increased Specificity and Sensitivity by applying a combined two test strategy


Show Resources
You May Also Like
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
SEP 13, 2022 8:00 AM PDT
SEP 13, 2022 8:00 AM PDT
Date: September 13, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Preparedness against pandemic diseases demands rapid-response vaccine technology and ready-to-use analytical methods...
MAR 23, 2022 11:00 AM PDT
MAR 23, 2022 11:00 AM PDT
Date: March 23, 2021 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEDT) In this presentation, Dr. Middleton will review the development and deployment of large-scale saliva-based COVID-19 test...
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
JUN 29, 2022 8:00 AM PDT
JUN 29, 2022 8:00 AM PDT
Date: June 29, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CEST) As of May 2022, there have been more than 500 million confirmed cases of COVID-19, including numerous variants. Additiona...
Loading Comments...
Show Resources